Survival Data for 299 Patients with Primary Cutaneous Lymphomas: A Monocentre Study

Abstract

The aim of this study was retrospectively to assess the validity of the 2005 WHO-EORTC classification for primary cutaneous lymphomas (PCL) in a large cohort of patients of a single German skin cancer unit. All patients with PCLs consecutively visiting our hospital between January 1980 and December 2005 were included in a retrospective monocentre study, analysing their histological and clinical data. A total of 312 patients fulfilled the inclusion criteria for PCL. In 299 patients clinical information and paraffin material were sufficient for detailed classification. Of the 299 patients, 63% expressed a T-cell and 37% a B-cell phenotype. Mycosis fungoides was the entity with the highest frequency (30.9%), followed by primary cutaneous follicle centre lymphomas (16.9%) and lymphomatoid papulosis (15.9%). The mean follow-up period was 38.4 months. Five-year disease-specific survival was 80.5% for mycosis fungoides, 92.5% in primary cutaneous anaplastic large cell lymphoma, 100% in lymphomatoid papulosis, 98.1% in primary cutaneous follicle center lymphoma, 100% in primary cutaneous marginal zone lymphoma and 63.2% in diffuse large B-cell lymphoma, leg type. Our data are in line with the data collected by the WHO-EORTC. This is further evidence for the reliability of the WHO-EORTC classification and staging system.

Early lymphoid lesions: conceptual, diagnostic and clinical challenges

“…75,76 PCMZL is an indolent disease with a 5-year disease-specific survival of over 95%. 77 Staging procedures with whole body imaging are recommended to rule out cutaneous involvement by MZL at other sites. Solitary lesions are excised with a "watch and wait" approach.…”

“…75,76 PCFCL has an excellent prognosis with more than 95% 5-year survival. 73,77 Small, well-demarcated solitary lesions are treated with surgical excision or radiation therapy with 40-70% of patients having cutaneous relapses. 78 Patients with few scattered lesions are treated with both radiotherapy of all visible skin lesions and a "waitand-watch" approach.…”

Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France

“…[1][2][3][4][5][6][7] In contrast with the more frequent other subtypes of cutaneous B-cell lymphomas (ie, primary cutaneous marginal zone B-cell lymphoma and primary cutaneous follicle center lymphoma), PCDLBCL-LT has a poor prognosis, with 5-year survival rates ranging from 41.0% to 73.1% in studies 4,6,[8][9][10][11] and approximately 50% to 55% in most reviews. 1,7,12,13 A combination of rituximab and the standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen has been recognized as the standard therapy for patients with DLBCLs.…”

Catalase, carbonic anhydrase and xanthine oxidase activities in patients with mycosis fungoides

“…One of these biochemical markers that has been increasingly investigated is oxidative stress which has been implicated in the pathogenesis of solid tumors, Alzheimer's and other neurodegenerative diseases 18 . MF is the most common type of cutaneous lymphomas in which lymphocytes become malignant and affect the skin 19 . MF may move through patch, plaque and tumor phase 2 .…”